Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Compound Clove Basil Dry Suspension is a fixed-dose combination pharmaceutical product developed by Xi'an Xintong Pharmaceutical Research Co., Ltd. for the treatment of acute diarrhea. The formulation is based on traditional medicinal knowledge, utilizing the antimicrobial and antispasmodic properties of clove (Syzygium aromaticum) and basil (Ocimum basilicum). Clove's primary active constituent, eugenol, provides significant antibacterial activity against common enteric pathogens and reduces intestinal motility. Basil contributes complementary anti-inflammatory and digestive-supportive effects. The drug is typically administered orally as a dry suspension and has been evaluated in Phase 3 clinical trials against standard treatments like smecta for adult patients with acute diarrhea.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on clove + basil.